✷ Report Code: A04249 | Mar 2022 | Pages: 180 | ||
Tables: 90 | Charts: 51 |
|
The outbreak of COVID-19 has disrupted workflows in the healthcare sector across the globe. The disease has forced a number of industries to shut their operations temporarily, including several sub-domains of healthcare. The COVID-19 pandemic led to disruptions in healthcare facilities. COVID-19 pandemic positively impacted key players in aSAH drugs market. Hemorrhagic cerebrovascular events, either due to aneurysmal rupture or spontaneous subarachnoid hemorrhage (SAH), are not rare in COVID-19. Several mechanisms such as coagulopathy, cytokine storm, viral endotheliopathy, hypertension, and immune modulation might play a role in the pathogenesis of SAH in COVID-19. Furthermore, during lockdown, patients faced difficulties with their ongoing treatment. However, community-dwelling individuals with disability were given special permission to go out for physical therapy and rehabilitation services. Moreover, patients suffering from aSAH had to switch to tele-medicine during the lockdown as they could not visit the hospitals.
Hypertension is one of the major factors that can lead to aSAH. As per the Centers for Disease Control and Prevention, about 70.0 million American adults suffer from high blood pressure, of which the condition of only 52.0% is under control. Moreover, according to the Centers for Medicare and Medicaid Services the U.S. healthcare expenditures grew from 4.6% to $3.8 trillion in 2019 and accounted for 17.7% of gross domestic product (GDP). In addition, the federal government accounted for 29 % of total health expenditures, followed by households with 28.4%. State and local governments accounted for 16.1% of total health care expenditures, while other private revenues accounted for 7.5%.
Furthermore, incidence of high blood pressure has increased, costing the U.S. $46.0 billion annually, which include the cost of healthcare services, medications to treat high blood pressure, and missed days of work.
In addition, increase in prevalence diseases such as stroke and hypertension and surge in geriatric population drive the growth of the aSAH drugs market. In addition, lifestyle changes, including increase in alcohol consumption and smoking rise the risk for aSAH, which, in turn, stimulates the market growth.
However, the associated side effects of drugs and medication taken during the treatment of aSAH restrain the aSAH drugs market share.
The aSAH drugs market is segmented on the basis of drug class and region. On the basis of drug class, the market is classified into opioid analgesic, calcium channel blocker, anticonvulsants, stool softeners, osmotic agents/diuretics, and other drugs. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA
Depending on drug class, the calcium channel blocker segment dominated the market and is expected to continue this trend during the forecast period, owing to increasing prevalence rate of cardiovascular diseases, changing lifestyle and hypertension. Rising assistance to people with anxiety disorders or bipolar disorder is also expected to help in the growth of the aneurysmal subarachnoid hemorrhage drugs market. In addition, increase patient awareness level, availability of the treatment options and vulnerable geriatric population are some of the influencing factors propelling the growth of the calcium channel blocker aSAH drugs market growth.
Region wise, North America dominated the market in 2020, owing to favorable healthcare infrastructure, which facilitated access to advanced aSAH drugs. In addition, government initiatives, including the Precision Medicine and Affordable Care Act, along with well-planned reimbursement policies, contributed to the market growth in North America. Moreover, surge in awareness among people and high purchasing parity resulted in increased demand for these devices. However, Asia-Pacific is expected to witness considerable market growth during the forecast period, due to rise in government support to enhance healthcare infrastructure. Economic developments in countries, including India and China, with higher disposable incomes fuel the demand for product. Moreover, China is expected to grow at high CAGR in, thereby making Asia-Pacific a aSAH drugs market opportunity.
The major companies profiled in this report include Azurity Pharmaceuticals, Johnson & Johnson, MediCure, NeurOp, Orexo AB, Pfizer, Inc., Pharmaxis, Ltd., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and Vitrais, Inc.
Key Benefits For Stakeholders
Aneurysmal Subarachnoid Hemorrhage Drugs Market Report Highlights
Aspects | Details |
---|---|
By Drug Class |
|
By Region |
|
Key Market Players | teva pharmaceutical industries ltd., orexo ab, Azurity Pharmaceuticals, Sun Pharmaceutical Industries Ltd., Vitrais, Inc, medicure, Pfizer, Inc., NeurOp, Johnson and Johnson, Pharmaxis, Ltd. |
According to the analyst’s perspective, diseases such as hypertension and stroke constitute major proportion of health and economic concern across the globe; hence, the development of effective medication is the major necessity for their treatment.
The major factors that contribute to the market growth include change in lifestyle and rise in geriatric population. In addition, lifestyle changes that include surge in alcohol consumption and smoking rise the risk for aSAH, which accelerate the market growth. Along with this, surge in geriatric population are also prevailing the growth of the aneurysmal subarachnoid hemorrhage drugs market. However, associated side effects of the drugs are expected to restrain the market growth. In addition, need to create awareness about the optimal diagnosis and treatment of aneurysmal subarachnoid hemorrhage is expected to provide lucrative opportunities for the market growth.
North America is anticipated to dominate the aneurysmal subarachnoid hemorrhage drugs market throughout the forecast period, owing to increase in incidence of people suffering from hypertension, followed by Europe and Asia-Pacific.
A. The Aneurysmal Subarachnoid Hemorrhage Market is currently growing at a CAGR of 3.6% from 2021-2030.
A. Drug types such as Opioid Analgesic, Calcium Channel Blocker, Anticonvulsant, Stool Softener, Osmotic Agents/Diuretics which are off label drugs are used in treating Aneurysmal Subarachnoid Hemorrhage.
A. Estimated industry size of Aneurysmal Subarachnoid Hemorrhage Drugs Market is USD 323.5 Million in 2020
A. Largest regional market for Aneurysmal Subarachnoid Hemorrhage Drugs Market is North America.
A. Azurity Pharmaceuticals, Johnson and Johnson, MediCure, NeurOp, Sun Pharmaceutical Industries Ltd. and Teva Pharmaceutical Industries Ltd.
Start reading instantly.
This Report and over 66,782+ more Reports, Available with Avenue Library. T&C*.
Enterprise
License/PDF
Library
Membership
*Taxes/Fees, if applicable will be added during checkout. All prices in USD
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.
Get Industry Data AlertsTo ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers